Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01155-y
Abstract: Belantamab mafodotin is a fi rst-in-class humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F [1]. Preclinical studies showed belantamab mafodotin interacts synergistically with standard-of-care agents for multiple… read more here.
Keywords: mafodotin; trial; phase dreamm; belantamab mafodotin ... See more keywords